Upstream Bio (UPB) Cash & Equivalents (2023 - 2026)

Upstream Bio's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $96.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 35.63% year-over-year to $96.7 million; the TTM figure through Mar 2026 stood at $96.7 million (up 35.63% YoY), while the FY2025 annual figure was $101.6 million, down 68.36% from the prior year.
• Cash & Equivalents was $96.7 million for Q1 2026 at Upstream Bio, down from $101.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $321.0 million in Q4 2024 to a low of $25.8 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $81.2 million across 4 years, with a median of $47.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 1142.6% in 2024, then slumped 68.36% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $25.8 million in 2023, then surged by 1142.6% to $321.0 million in 2024, then plunged by 68.36% to $101.6 million in 2025, then retreated by 4.78% to $96.7 million in 2026.
• The last three Cash & Equivalents figures came in at $96.7 million (Q1 2026), $101.6 million (Q4 2025), and $72.2 million (Q3 2025), per Business Quant data.